Navigation Links
diaDexus, Inc. Reports 45% Year-Over-Year Revenue Growth for 2011 Second Quarter
Date:8/15/2011

SOUTH SAN FRANCISCO, Calif., Aug. 15, 2011 /PRNewswire/ -- diaDexus, Inc. (OTC Bulletin Board: DDXS), a diagnostics company focused on the development and commercialization of patent-protected in vitro diagnostic products addressing unmet needs in cardiovascular disease, today announced financial results for the second quarter of 2011.

Total revenues for the quarter ended June 30, 2011 were $3.8 million, representing 45% growth over total revenues of $2.6 million for the second quarter of 2010, and a 15% increase over first quarter 2011 revenues. Total operating costs and expenses for the quarter were $6.3 million as compared to $4.6 million for the 2010 second quarter, with the increase in expenses primarily related to the requirements of public company reporting, costs associated with a building lease entered into by VaxGen, Inc. prior to the July 2010 reverse merger transaction, and severance costs related to the resignation of the company's former CEO.  Net cash used in operating activities for the second quarter of 2011 declined to $1.4 million versus $1.8 million for the same period the year prior, and down from $1.9 million in the first quarter of 2011.

As of June 30, 2011, diaDexus had cash, cash equivalents, and investments of $16.8 million, compared to $18.5 million at March 31, 2011.

Commenting on the financial results, Interim Chief Executive Officer James Panek stated, "The second quarter results reflect better than expected sales of our PLAC ELISA Test to several laboratory customers, and marks our fourth consecutive quarter of revenue growth. The strength of our sales during the first half of 2011 has largely mitigated the impact of not reintroducing the PLAC TIA product, and we believe that we will achieve full year total revenues at the upper end of our previous guidance for 2011."

Guidance

diaDexus said that it expect
'/>"/>

SOURCE diaDexus, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. diaDexus, Inc. and Living Heart Foundation Offer the PLAC(R) Test to Detect Hidden Risk for Heart Attack and Stroke in Retired NFL Players
2. SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results
3. AutoImmune Inc. Reports 2008 Second Quarter Financial Results
4. Par Pharmaceutical Reports Second Quarter 2008 Results
5. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
6. Pharmos Corporation Reports 2008 Second Quarter Results
7. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
8. MGT Capital Investments Reports Second Quarter 2008 Financial Results and Provides Update on Recent Developments
9. BMP Sunstone Reports Second Quarter 2008 Financial Results
10. ULURU Inc. Reports Second Quarter 2008 Financial Results
11. Immtech Reports Fiscal First Quarter 2009 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... ... August 26, 2015 , ... MediVet Biologics, ... second US laboratory is to open in Manhattan, Kansas in early October, 2015. ... long-term growth of research and development through collaboration with researchers from Kansas State ...
(Date:8/26/2015)...  Platform therapeutic company Symic Biomedical, Inc. ("Symic") ... Phase II SBIR grant from the National Institutes ... agent to reduce arteriovenous fistula (AVF) failures, a ... disease (ESRD) patients undergoing hemodialysis. The two-year project, ... Digestive and Kidney Diseases (NIDDK), will allow Symic ...
(Date:8/26/2015)... 2015 Despite recent market ... optimism in biotech,s forecast is the recent run ... advancements.  Active biotechnology & healthcare companies with recent ... PBIO), Sequenom, Inc. (NASDAQ: SQNM ), Sarepta ... Corp. (NASDAQ: RPTP ) and EnteroMedics Inc. ...
(Date:8/25/2015)... Wis. (PRWEB) , ... August 25, 2015 , ... ... fermentor at its research facility in Knapp, Wis. The company has added a ... C15 Fermentor allows detailed data collection during bacterial or fungal fermentation process development. ...
Breaking Biology Technology:MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 3Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 2New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 3New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 4New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 5New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 6New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 7New centrifuge and fermentor expand product development capacity at Vets Plus 2
... Sangamo BioSciences, Inc. (Nasdaq: SGMO ) today announced ... year 2011 financial results on Wednesday, February 8, 2012, after ... a conference call at 5:00 p.m. ET, which will be ... conference call, the company will review the financial results and ...
... 1, 2012  Generex Biotechnology Corporation (OTCBB: GNBT.OB) announced ... Inc., has been awarded a Japanese Patent centering ... immunotherapeutic vaccines.  A number of products developed with ... patent helps to secure the novel Antigen Express ...
... The report " Biomarkers Market (Discovery ... & Forecasts (2011   -   2020) " , ... drivers, restraints, and opportunities in North America, Europe, Asia, and ... data tables and in-depth TOC on the   ...
Cached Biology Technology:Sangamo BioSciences Announces Fourth Quarter and Full Year 2011 Conference Call and Webcast 2Generex Announces Patent Award for its Core Vaccine Technologies in Japan 2Generex Announces Patent Award for its Core Vaccine Technologies in Japan 3Generex Announces Patent Award for its Core Vaccine Technologies in Japan 4MarketsandMarkets: Global Biomarkers Market worth $25.79 Billion by 2016 2MarketsandMarkets: Global Biomarkers Market worth $25.79 Billion by 2016 3
(Date:8/6/2015)... REDWOOD CITY, Calif. , Aug. 6, 2015 ... (D-Silicon Valley) will visit Crossmatch ™ to ... secure networks and protect data. Crossmatch is a ... solutions whose technologies and expertise are helping federal ... operational efficiency and security.   "The ...
(Date:8/5/2015)... 5, 2015 Transparency Market Research ... Market - Global Industry Analysis, Size, Share, Growth, Trends ... facial recognition is forecast to reach US$ 2,671.8 Mn ... for surveillance systems by civil and government agencies. This ... and terrorist activities across the globe that would elevate ...
(Date:8/3/2015)... SAN JOSE, Calif. , Aug. 3, 2015 /PRNewswire/ ... developer of human interface solutions, today announced that members ... investment community at the Pacific Crest Global Technology Leadership ... Mountain Time. The conference will be held at the ... The presentation may include forward-looking information. ...
Breaking Biology News(10 mins):Rep. Honda to Visit Crossmatch in Redwood City 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 4Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 5Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 6
... are increasingly obtaining endangered or threatened plants, often illegally, and ... in the journal Nature by Patrick Shirey and ... University of Notre Dame. According to their research last ... threatened and endangered under the US Endangered Species Act are ...
... Alberta researchers determined that a fossilized dinosaur bone found in ... of dinosaurs ended between 65.5 and 66 million years ago. ... Larry Heaman from the Department of Earth and Atmospheric Sciences, ... 64.8 million years old. That means this particular plant eater ...
... Visionaries in the field of cardiac therapeutics have long looked ... or repaired by using one,s own heart cells. A study ... scientific journal of the American Heart Association, shows that heart ... to rebuild the damaged heart in the laboratory. ...
Cached Biology News:Notre Dame biologists call for regulation of rare plant sales 2Test shows dinosaurs survived mass extinction by 700,000 years 2Stem cells show promise in repairing a child's heart 2
... with new technology incorporating the sophisticated ... flexibility, the new Varian NMR System ... available today., ,The Varian NMR System ... and receiver channel, providing pulse sequence ...
...
Homo sapiens inhibin, beta B (activin AB beta polypeptide) Antigen: Recombinant Protein(142~254aa)...
... in your 35mm dish without transferring ... Chamber has separate openings for solution ... fluctuations of the liquid level in ... from entering the chamber. An adjustable ...
Biology Products: